Fredun [FREDUN] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Fredun Pharmaceuticals Ltd.

BSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Fredun Pharmaceuticals Ltd. wins in 8 metrics, Divi's Laboratories Ltd. wins in 12 metrics, with 0 ties. Divi's Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Fredun Pharmaceuticals Ltd. Divi's Laboratories Ltd. Better
P/E Ratio (TTM) 29.83 67.11 Fredun Pharmaceuticals Ltd.
Price-to-Book Ratio 6.26 10.82 Fredun Pharmaceuticals Ltd.
Debt-to-Equity Ratio 108.78 0.58 Divi's Laboratories Ltd.
PEG Ratio 0.31 4.63 Fredun Pharmaceuticals Ltd.
EV/EBITDA 13.98 48.63 Fredun Pharmaceuticals Ltd.
Profit Margin (TTM) 5.53% 24.04% Divi's Laboratories Ltd.
Operating Margin (TTM) 15.26% 29.65% Divi's Laboratories Ltd.
EBITDA Margin (TTM) 15.26% 29.65% Divi's Laboratories Ltd.
Return on Equity 13.96% 14.64% Divi's Laboratories Ltd.
Return on Assets (TTM) 4.05% 12.94% Divi's Laboratories Ltd.
Free Cash Flow (TTM) $-351.69M $2.15B Divi's Laboratories Ltd.
Dividend Yield 0.09% 0.91% Divi's Laboratories Ltd.
1-Year Return 183.86% -0.43% Fredun Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 1.93 16.18 Fredun Pharmaceuticals Ltd.
Enterprise Value $11.27B $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 1.91 15.86 Fredun Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 28.72% 63.71% Divi's Laboratories Ltd.
Revenue per Share (TTM) $1,273 $388 Fredun Pharmaceuticals Ltd.
Earnings per Share (Diluted) $69.90 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) 0.46 0.19 Divi's Laboratories Ltd.

Fredun Pharmaceuticals Ltd. vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

FREDUN
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Fredun Pharmaceuticals Ltd.0.17%0.73%-2.19%43.43%39.40%50.67%
Divi's Laboratories Ltd.-0.44%1.34%-2.25%8.85%4.11%4.17%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Fredun Pharmaceuticals Ltd.183.86%158.56%447.18%11,453.75%18,386.00%18,386.00%
Divi's Laboratories Ltd.-0.43%85.44%58.15%496.33%1,610.60%10,946.76%

Performance & Financial Health Analysis: Fredun Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricFREDUNDIVISLAB
Market Information
Market Cap i₹11.55B₹1.69T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i11,259253,443
90 Day Avg. Volume i9,301283,911
Last Close₹2,314.65₹6,608.50
52 Week Range₹791.00 - ₹2,620.00₹5,636.50 - ₹7,071.50
% from 52W High-11.65%-6.55%
All-Time High₹2,620.00 (May 25, 2026)₹7,071.50 (Jul 08, 2025)
% from All-Time High-11.65%-6.55%
Growth Metrics
Quarterly Revenue Growth0.57%0.12%
Quarterly Earnings Growth0.97%-0.01%
Financial Health
Profit Margin (TTM) i0.06%0.24%
Operating Margin (TTM) i0.15%0.30%
Return on Equity (TTM) i0.14%0.15%
Debt to Equity (MRQ) i108.780.58
Cash & Liquidity
Book Value per Share (MRQ)₹333.11₹580.95
Cash per Share (MRQ)₹18.49₹122.95
Operating Cash Flow (TTM) i₹-1,140,997,000₹19.67B
Levered Free Cash Flow (TTM) i₹197.39M₹21.91B
Dividends
Last 12-Month Dividend Yield i0.09%0.91%
Last 12-Month Dividend i₹0.70₹60.00

Valuation & Enterprise Metrics Analysis: Fredun Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricFREDUN (Apr 24, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i29.8367.11
Forward P/E iN/A53.75
PEG Ratio i0.314.63
Price to Sales (TTM) i1.9316.18
Price to Book (MRQ) i6.2610.82
Market Capitalization
Market Capitalization i₹11.55B₹1.69T
Enterprise Value i₹11.27B₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i1.9115.86
Enterprise to EBITDA i13.9848.63
Risk & Other Metrics
Beta i0.460.19
Book Value per Share (MRQ) i₹333.11₹580.95

Financial Statements Comparison: Fredun Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricFREDUN (2025)DIVISLAB (2025)
Revenue/Sales i4.52B93.25B
Cost of Goods Sold i3.45B38.70B
COGS % of Revenue i76.5%41.5%
Gross Profit i1.06B54.55B
Gross Margin i23.5%58.5%
Research & Development i49.76M270.00M
Operating Income (EBIT) i475.31M25.71B
Operating Margin i10.5%27.6%
EBITDA i530.69M33.19B
EBITDA Margin i11.7%35.6%
Pre-Tax Income i274.94M29.16B
Pre-Tax Income % of Revenue i6.1%31.3%
Income Tax i77.54M7.25B
Income Tax % of Revenue i1.7%7.8%
Net Income (Profit) i197.39M21.91B
Profit Margin i4.4%23.5%

Balance Sheet & Liquidity Metrics

MetricFREDUN (2025)DIVISLAB (2025)
Cash & Equivalents i6.37M4.15B
Total Current Assets i4.28B100.81B
Total Current Assets % of Revenue i94.7%108.1%
Total Current Liabilities i3.28B14.52B
Total Current Liabilities % of Revenue i72.6%15.6%
Long-Term Debt i96.13M20.00M
Long-Term Debt % of Revenue i2.1%0.0%
Total Shareholders Equity i1.41B149.69B
Retained Earnings i628.39M134.00B
Retained Earnings % of Revenue i13.9%143.7%
Property, Plant & Equipment i95.24M3.19B

Cash Flow Statement Comparison

MetricFREDUN (2025)DIVISLAB (2025)
Operating Cash Flow i-1.14B19.67B
Operating Cash Flow % of Revenue i-25.3%21.1%
Capital Expenditures i-59.94M-14.38B
Free Cash Flow i-351.69M2.15B
FCF Margin i-7.8%2.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricFREDUNDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i5.47M265.47M
Float Shares i534,241117.72M
% Held by Insiders i53.36%52.04%
% Held by Institutions i0.00%28.65%
% Held by Public i46.64%19.31%

Dividend Analysis & Yield Comparison: Fredun Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricFREDUNDIVISLAB
Last 12-Month Dividend i₹0.70₹60.00
Last 12-Month Dividend Yield i0.09%0.91%
3-Year Avg Annual Dividend i₹0.70₹50.00
3-Year Avg Dividend Yield i0.08%0.70%
3-Year Total Dividends i₹2.10₹150.00
Ex-Dividend DateSep 23, 2024Jul 25, 2025